Background: Thrombolytic therapy with urokinase 5000 units has been the standard therapy for the restoration of thrombosed central catheters. However, with the decreased availability of urokinase, alternatives needed to be sought. The aim of the study was to determine the efficacy, bioactivity, dwell time and cost of cryopreserved recombinant tissue plasminogen activator (rTPA) in the restoration of occluded central venous access devices.
Materials And Methods: For children < 10 kg, a dose of 0.5 mg, and for children >10 kg, a dose of 1mg was used. The dwell time was 1-2 hours.
Results: Of the 40 courses of rTPA, 39 fully restored central venous line patency (97%). Successful courses were instilled for an average of 1 hour.
Conclusion: Cryopreserved rTPA appears to be safe and effective in the dose used to restore the patency of occluded central venous access devices in pediatric oncology patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.5144/0256-4947.2002.300 | DOI Listing |
Vascular
January 2025
Department of Vascular Surgery, Miller Family Heart Vascular and Thoracic Institute, Cleveland Clinic, Cleveland, OH, USA.
Objective: Superior vena cava syndrome (SVC) is a debilitating disease, and surgical reconstruction has been described with some of the best results using spiral great saphenous vein (SGSV) grafts. SGSV grafts can be difficult to construct, and a long segment of saphenous vein is needed. Femoral vein has been an excellent conduit for infected aortic and peripheral reconstructions in our hands, and we sought to review outcomes using this conduit for SVC reconstruction.
View Article and Find Full Text PDFNurs Crit Care
January 2025
Department of Nursing, the First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Background: Central venous catheters (CVCs) are placed where the vena cava meets the right atrium. Their common use raises the risk of catheter-related thrombosis (CRT), a potentially life-threatening complication.
Aim: This study leverages machine learning to develop a CRT predictive model for abdominal surgery patients, aiming to refine clinical decisions and elevate treatment quality.
J Clin Apher
February 2025
University of Kansas Medical Center, Division of Hematologic Malignancies and Cellular Therapeutics, Kansas City, Kansas, USA.
Apheresis is essential to conducting hematopoietic cell transplantation and genetically engineered cellular therapy procedures. Many patients and donors require central venous catheter (CVC) access for apheresis due to lack of adequate peripheral venous access. CVC placement has risks of associated complications and requires additional institutional resources and expertise.
View Article and Find Full Text PDFHematology
December 2025
Intensive medicine department, Lishui traditional Chinese medicine hospital, Lishui City, People's Republic of China.
Objective: This review aimed to examine if there is any difference in the risk of thrombosis and central line-associated bloodstream infection (CLABSI) with the use of peripherally inserted central catheter (PICC) and conventional central venous catheters (CVC) in hematological cancer patients.
Methods: We searched the online databases of PubMed, CENTRAL, Scopus, Web of Science, and Embase for all types of studies comparing the risk of thrombosis and CLABSI between PICC and CVC. The search ended on 23rd September 2024.
Anesthesiology
February 2025
Department of Anaesthesia and Pain Management, The Royal Children's Hospital, Melbourne, Australia; Department of Paediatrics, The University of Melbourne, Melbourne, Australia; Anaesthesia Research Group and Haematology Research Group, Murdoch Children's Research Institute, Melbourne, Australia.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!